Rybelsus, the first oral GLP-1 receptor agonist approved for the treatment of type 2 diabetes, offers significant insight into the complex landscape of drug pricing and access equity. Its high price point has ignited debates surrounding access and financial sustainability for patients and healthcare systems alike. As the conversation surrounding…